MONCTON, NB (DECEMBER 14, 2017) - Tieös Pharmaceuticals, a next-generation biotech company focused on cancer metabolic therapies, is pleased to announce that it has joined the Emergence Bioscience Business Incubator as it continues to progress in its drug development initiatives and plan for its next phase of growth.
The Emergence Bioscience Business Incubator is a not-for-profit virtual business incubation program dedicated to assisting innovative start-ups and growth stage companies in the bioscience and food sectors. Emergence is a multi-year incubation program that provides clients with customized support and guidance to help bring their products and services to market.
“We are pleased to welcome Tieös to our incubator program and are impressed by the progress they have made thus far,” said Martin Yuill, Director of the Emergence Incubator. “The team at Tieös has a compelling story and we’re excited to be able to support them on their very promising journey.”
As a virtual incubator, Emergence serves high-potential companies wherever they are located in Canada, while also providing a “soft landing” for innovative international bioscience ventures seeking to start-up or establish themselves in, or expand into, Canada.
“As we continue to make excellent progress in our drug development, we are excited to be joining a nationally-recognized initiative such as Emergence,” said Arun Anand, CEO of Tieös Pharmaceuticals. “Emergence provides us with a unique opportunity to connect with experts in our field and to accelerate many of our development plans for continued growth via access to their targeted mentorship, advisory and consulting services.”
About Emergence Bioscience Business Incubator
Emergence is a virtual business incubator that supports the formation and growth of innovative bioscience and food sector ventures. Emergence clients benefit from access to business, technical, scientific and regulatory support services customized to meet their individual needs. This includes one-on-one and team-based mentorship; third-party consulting services; market research; legal, IP, insurance, tax and financial expertise from a network of professional service provider partners; and support accessing international networks and public and private funding and investment opportunities.
About Tieös Pharmaceuticals
Tieös Pharmaceuticals is a privately held pre-clinical stage biotech company, focused on developing novel small molecule inhibitors which target the unique metabolic characteristics of cancer cells. Tieös’ lead compounds in development target multiple metabolic pathways simultaneously, while utilizing intelligent drug design elements to minimize drug resistance and collateral damage to healthy and vital cells. Founded in 2016, the company has offices in Ontario and New Brunswick, Canada. For more information, visit www.tieospharma.ca